Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced the Australian Research Council (ARC) had awarded a Linkage Grant of $340,000 to a research consortium that includes Regeneus collaborating with leading researchers from Macquarie University and the University of Adelaide.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced completion of enrolment of all 20 patients in the STEP trial. Further, a review of the cumulative study safety data by the study safety oversight committee identified no safety concerns.
The Life Sciences Report: Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Regeneus Ltd (ASX:RGS) Achieved better than targeted net operating cash flow for the quarter. Cash outflow for the quarter was $1.44 million. Cash flow is tracking consistently better than the target of $1.70 million per quarter.
Orion Health (NZE:OHE) (ASX:OHE) has today announced it has signed two contracts that will significantly extend its presence in the United Kingdom. It will provide a comprehensive technology solution for two leading hospitals in London, and it will implement an integrated health and social care solution for NHS Fife in east Scotland.
iQ3Corp Ltd (ASX:iQ3) is pleased to announce that it has syndicated an investor consortium which include iQ Group Global entities, to enter into a joint venture to develop and commercialise a first in class oncology, novel biologic compound and biomarker.
Medigene AG (FRA:MDG1), a clinical stage immune-oncology company focussing on the development of T cell-based immunotherapies for the treatment of cancer, announces that it has today sold 50% of its' stake in the private biotech company Immunocore Ltd., UK, for approximately 4.9 million GBP (approx. EUR 6.1 million).
